You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
NEW YORK – Metastatic colon cancer patients are being undertested for guidelines-backed genomic markers, which means that many of them are losing out on the chance to receive precision therapies, a recently published study suggests.
Premium Access gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Molecular tumor profiling has provided extensive value, both in tumor biology and oncology, with the development of new technologies to identify biomarkers.
This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.
Most recent single-cell and spatial biology studies have focused on the network of interactions between different cell types and their spatial context.